Stiris Research Inc. Awarded Rescue Study for Hepatorenal-Syndrome

London, ON — August 8, 2022 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it has been awarded a Phase II rescue study in Hepatorenal-Syndrome and Acute Kidney Injury (HRS-AKI).

“We are thrilled to have the opportunity to support this Sponsor in expanding this trial into Canada and with additional sites in the US. This is a complex study with a lot of moving parts in a high-risk patient population that experiences poor outcomes and extended stays in hospital. Through collaboration with the Sponsor, and an adaptive team at Stiris, we are confident that this will be a successful study and hope to be an integral piece in bringing a treatment solution to these patients.” Said Michael Sawras, Project Manager.

 Hepatorenal syndrome (HRS) is a form of impaired kidney function that occurs in individuals with advanced liver disease. Individuals with hepatorenal syndrome do not have any identifiable cause of kidney dysfunction and the kidneys themselves are not structural damaged. Blood circulation is abnormal in individuals with hepatorenal syndrome. The arteries that circulate oxygenated blood from the lungs to the rest of the body widen in contrast to the arteries of the kidney, which narrow causing a decrease in the blood flow through the kidney. (,themselves%20are%20not%20structural%20damaged.)

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.